Teresa Koeller, MD
Addiction Medicine · Covington, KYNPI 1457399917
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,360 of the $3,281 with a category attached, or 71.9%. 16 manufacturers reported payments, led by Titan Pharmaceuticals, Inc. at 29.4% of the total. Reporting peaked in 2019 at $1,280 and has fallen 57.6% since, to $543 in 2025.
Across 122 payments — averaging $26.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Titan Pharmaceuticals, Inc.$964
- AbbVie$648
- Indivior Inc.$425
- Alkermes, Inc.$359
- Braeburn Inc.$176
- Johnson & Johnson$142
- plus $567 from 10 others
What the payments were for
- Travel & lodging$92128%
- Food & beverage$2,36072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Titan Pharmaceuticals, Inc. | 2 | $964 |
| AbbVie | 31 | $648 |
| Indivior Inc. | 18 | $425 |
| Alkermes, Inc. | 23 | $359 |
| Braeburn Inc. | 15 | $176 |
| Johnson & Johnson | 2 | $142 |
| Axsome Therapeutics, Inc. | 6 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $106 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| MDD US Operations, LLC | 4 | $60 |
| USWM, LLC | 3 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Orexo US, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Probuphine$921
- SPRAVATO$125
- SUBLOCADE$115
How this compares
$3,281 in reported general payments places this provider in the 80th percentile of 40 addiction medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 58 | $1,598 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Covington
- Oliver BenesCovington$3K
- Mina KalfasCovington$2K
- Kathleen YangCovington$245
- Anastasia JandesLexington$55K
- Rallie McAllisterLexington$17K
- Michael KindredLexington$13K
- Asad IsmailLouisville$10K
- Guy LernerElizabethtown$10K
- Joseph KoenigsmarkShepherdsville$3K
- Barry HardisonCentral City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.